

RECEIVED
CENTRAL FAX CENTER

JAN 31 2006

CERTIFICATION OF FACSIMILE TRANSMISSION

I hereby certify that this paper is being facsimile transmitted to the Patent and Trademark Office on the date shown below.
FAX No.: 571-273-8300

Kim Landers

Type or print name of person signing certification

Kim Landers

Signature

Jan. 31, 2006

Date

PATENT
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:	Chin-Ming Chang and Henry A. Havel)	
Serial No.:	10/055,509)	
Filed:	January 23, 2002)	Group Art Unit:
)	1654
)	
For:	Stablized Teriparatide Solutions)	Examiner:
)	A Gupta
Docket No.:	X-10911A)	

TERMINAL DISCLAIMER UNDER 37 C.F.R. 1.321

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Identification of Person Making This Disclaimer

I, Thomas D. Webster, am employed by Eli Lilly and Company, and I am an attorney of record in the above-identified patent application. In that capacity, I am authorized to sign this disclaimer on behalf of Eli Lilly and Company.

Identity of Assignee

I hereby verify that the assignee owning all of the interest in this application is:

Eli Lilly and Company
Lilly Corporate Center
Indianapolis, Indiana 46285

02/01/2006 MBINAS 00000039 050040 10055509
01 FC:1814 130.00 DA

Serial No. 10/055,509

Recordal of Assignment in PTO

The assignment was recorded on May 31, 2000, Reel 010873, Frame 0809.

Extent of Interest

The extent of Eli Lilly and Company's interest is in the whole of this invention.

Disclaimer

I hereby disclaim the terminal part of any patent granted on this application, which would extend beyond the expiration date of:

U.S. Patent No. 6,770,623 and hereby agree that any patent granted on this application shall be enforceable only for and during such period that the legal title to the patent shall be the same as the legal title to U.S. Patent No. 6,770,623.

I do not disclaim any terminal part of any patent granted on this application prior to the expiration date of the full statutory term of U.S. Patent No. 6,770,623 in the event that it later: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid, is statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. 1.321, has all claims cancelled by a reexamination certificate, or is otherwise terminated prior to expiration of its full statutory term other than as presently shortened by any terminal disclaimer.

Fee Payment

Please charge \$110.00, the fee set forth in 37 C.F.R. 1.20(d), and charge any additional fees which may be required by this or any other related paper, or credit any overpayment to Deposit Account No. 05-0840 in the name of Eli Lilly and Company. Two copies of this disclaimer are enclosed.

ELI LILLY AND COMPANY

By: 

Thomas D. Webster, PhD
Registration No. 39,872
Phone: 317-276-3334